You are here

Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42AG073059-02
Agency Tracking Number: R42AG073059
Amount: $1,318,445.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NIA
Solicitation Number: PAS22-197
Timeline
Solicitation Year: 2022
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-09-15
Award End Date (Contract End Date): 2025-08-31
Small Business Information
13 RIDGEFIELD ROAD
Wayland, MA 01778-4340
United States
DUNS: 080793244
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ILYA ILIN
 (617) 459-9088
 ilya.ilyin.apt@gmail.com
Business Contact
 ILYA ILIN
Phone: (617) 459-9088
Email: ilya.ilyin@generalbiophysics.com
Research Institution
 BRIGHAM AND WOMEN'S HOSPITAL
 
75 FRANCIS STREET
BOSTON, MA 02115-6110
United States

 Domestic Nonprofit Research Organization
Abstract

PHASE II APPLICATION(STTR Program PAS-22-197)
“Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects”
ABSTRACTAlzheimer’s disease (AD) is one of the most prevalent neurodegenerative disorders. Emerging evidence
shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia,
plays a significant role in the onset and progression of the disease. Microglial function is maintained in healthy
brain and is pathogenically dysregulated in AD brain. The prominent genetic risk factor, APOE, is involved in
microglial function. We have recently identified a unique molecular signature for homeostatic microglia and have
developed robust tools to investigate microglial biology in health and disease. We also identified a role for the
APOE-signaling in the regulation of a new microglial subset associated with neurodegeneration and in microglia
surrounding neuritic Ab-plaques in human AD brain, which we have termed MGnD. The major question relates
to microglia-based approach to treat AD is how to modulate microglia phenotype and function. Preservation of
neuronal cells from Aβ-induced apoptosis as well as restoration of resident microglial homeostatic function is
critical for the restoration of brain function.The goal of this proposal is to perform Phase 1 clinical trial to evaluate the safety of Xe inhalation in
healthy normal volunteers given at increasing durations of exposure: 20, 40, 60, and 90 minutes. Xe is currently
used in human patients as an anesthetic and as a neuroprotectant in treatment of brain injuries. Xe penetrates
blood brain barrier, which can make it effective therapeutic. Our preliminary data demonstrated that Xe delivered
through inhalation: 1) modulates microglia from an MGnD to homeostatic phenotype in an acute
neurodegeneration model and in AD mice; 2) ameliorates AD-like pathology associated with decreased Ab-
plaques in APP/PS1 mice; 3) reduces APOE4-induced neurodegeneration and decreases brain atrophy in
P301S mice and 4) decreases monocyte infiltration and suppresses their proinflammatory response.
Mechanistically, we found that Xe treatment polarizes homeostatic microglia toward an intermediate state
(MGiS), via induction of microglial responses to IFNg signaling. Importantly, we identified the optimal PK/PD of
Xe inhalation treatment in an acute model of neurodegeneration and in AD mice. Successful completion of this
clinical trial proposal will be the first step of evaluation of xenon inhalational therapy in humans and will allow to
move to its evaluation in AD patients for safety and efficacy, leading to raising private-sector capital and initiation
of Phase 2 clinical trials in AD. Thus, we propose the following specific aim:
Aim: To evaluate the safety of Xe inhalation in healthy normal volunteers given at increasing durations
of exposure: 20, 40, 60, and 90 minutes.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government